142 related articles for article (PubMed ID: 19744184)
1. Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily.
Sillaber C; Herrmann H; Bennett K; Rix U; Baumgartner C; Böhm A; Herndlhofer S; Tschachler E; Superti-Furga G; Jäger U; Valent P
Eur J Clin Invest; 2009 Dec; 39(12):1098-109. PubMed ID: 19744184
[TBL] [Abstract][Full Text] [Related]
2. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
Tyler T
Ann Pharmacother; 2009 May; 43(5):920-7. PubMed ID: 19336654
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
Ghatnekar O; Hjalte F; Taylor M
Acta Oncol; 2010 Aug; 49(6):851-8. PubMed ID: 20615173
[TBL] [Abstract][Full Text] [Related]
6. [Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase].
Vinogradova OIu; Turkina AG; Vorontsova AV; Chelysheva EIu; Gusarova GA; Kuznetsov SV; Goriacheva SR; Sokolova MA; Abakumov EM; Stakhina OV; Domracheva EV; Misiurin AV; Khoroshko ND
Ter Arkh; 2009; 81(7):41-6. PubMed ID: 19708572
[TBL] [Abstract][Full Text] [Related]
7. [Clinical profiles of 7 patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia treated with dasatinib].
Hoshino T; Tahara K; Miyawaki K; Hatsumi N; Takada S; Miyawaki S; Sakura T
Rinsho Ketsueki; 2010 Mar; 51(3):181-8. PubMed ID: 20379112
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib: BMS 354825.
Drugs R D; 2006; 7(2):129-32. PubMed ID: 16542059
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
Luo FR; Yang Z; Camuso A; Smykla R; McGlinchey K; Fager K; Flefleh C; Castaneda S; Inigo I; Kan D; Wen ML; Kramer R; Blackwood-Chirchir A; Lee FY
Clin Cancer Res; 2006 Dec; 12(23):7180-6. PubMed ID: 17145844
[TBL] [Abstract][Full Text] [Related]
11. [Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].
Cony-Makhoul P; Bergeron A; Corm S; Dubruille V; Rea D; Rigal-Huguet F; Nicolini FE
Bull Cancer; 2008 Sep; 95(9):805-11. PubMed ID: 18829412
[TBL] [Abstract][Full Text] [Related]
12. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
Oweini H; Otrock ZK; Mahfouz RA; Bazarbachi A
Arch Gynecol Obstet; 2011 Jan; 283(1):133-4. PubMed ID: 20473616
[TBL] [Abstract][Full Text] [Related]
13. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients.
Tanaka H; Nakashima S; Usuda M
Int J Hematol; 2012 Sep; 96(3):308-19. PubMed ID: 22767140
[TBL] [Abstract][Full Text] [Related]
14. New dosing schedules of dasatinib for CML and adverse event management.
Wong SF
J Hematol Oncol; 2009 Feb; 2():10. PubMed ID: 19236716
[TBL] [Abstract][Full Text] [Related]
15. New approved dasatinib regimen available for clinical use.
Snyder DS
Expert Rev Anticancer Ther; 2009 Mar; 9(3):285-92. PubMed ID: 19275507
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events.
Shayani S
Ther Drug Monit; 2010 Dec; 32(6):680-7. PubMed ID: 20864900
[TBL] [Abstract][Full Text] [Related]
17. Pleural effusions due to dasatinib.
Brixey AG; Light RW
Curr Opin Pulm Med; 2010 Jul; 16(4):351-6. PubMed ID: 20375898
[TBL] [Abstract][Full Text] [Related]
18. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
19. Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.
Klamova H; Faber E; Zackova D; Markova M; Voglova J; Cmunt E; Novakova L; Machova-Polakova K; Moravcova J; Dvorakova D; Michalova K; Brezinova J; Oltova A; Jarosova M; Cetkovsky P; Indrak K; Mayer J
Neoplasma; 2010; 57(4):355-9. PubMed ID: 20429627
[TBL] [Abstract][Full Text] [Related]
20. Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib.
Latagliata R; Breccia M; Castagnetti F; Stagno F; Luciano L; Gozzini A; Ulisciani S; Cavazzini F; Annunziata M; Sorà F; Rossi AR; Pregno P; Montefusco E; Abruzzese E; Crisà E; Musto P; Tiribelli M; Binotto G; Occhini U; Feo C; Vigneri P; Santini V; Fava C; Rosti G; Alimena G
Leuk Res; 2011 Sep; 35(9):1164-9. PubMed ID: 21705080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]